SCHEMBL20510001

SCHEMBL20510001

COC(=O)c1cc(OCc2ccccc2)ccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
HPGD P15428 1/20 0.52
MAOB P27338 4/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
NR4A2 P43354 1/20 0.49
PKM P14618 1/20 0.48
SMPD1 P17405 1/20 0.48
P4HTM Q9NXG6 1/20 0.48
MRGPRX4 Q96LA9 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
GABRA1 P14867 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3713623 0.87 MCL1 (0.57) LMNAHPGDMAOBMEN1KMT2A
SCHEMBL3534571 0.85 LMNA (0.55) LMNAHPGDMAOBMEN1KMT2A
SCHEMBL11617562 0.85 P4HTM (0.60) HPGDMAOBMEN1KMT2ASMN1; SMN2
SCHEMBL18681644 0.84 CSF1R (0.54) MAOBMEN1KMT2ANR4A2SMPD1
SCHEMBL3712925 0.83 ACACB (0.58) LMNAHPGDMAOBMEN1KMT2A
SCHEMBL23488362 0.82 PARP10 (0.56) MAOBMEN1KMT2ASMN1; SMN2NR4A2
SCHEMBL3532550 0.82 LMNA (0.55) LMNAHPGDMAOBMEN1KMT2A
SCHEMBL24360100 0.82 PKM (0.53) LMNAMAOBKMT2ASMN1; SMN2RAB9A
SCHEMBL20812637 0.81 ANO1 (0.53) MAOBMEN1KMT2ASMPD1
SCHEMBL19859615 0.81 MAOB (0.46) MAOBMEN1KMT2ANR4A2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223285-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO LTD (CN) 2025-07-10 US disclosed
EP-3601239-B1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO LTD (CN) 2024-07-31 EP disclosed
WO-2024026338-A1 N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
CN-116003321-A Novel heterocyclic derivatives useful as SHP2 inhibitors 北京加科思新药研发有限公司 2023-04-25 CN disclosed
CN-115969853-A Novel heterocyclic derivatives useful as SHP2 inhibitors 北京加科思新药研发有限公司 2023-04-18 CN disclosed
CN-115721648-A Novel heterocyclic derivatives useful as SHP2 inhibitors 北京加科思新药研发有限公司 2023-03-03 CN disclosed
CN-112174935-B Heterocyclic derivatives useful as SHP2 inhibitors 北京加科思新药研发有限公司 2022-12-06 CN disclosed
CN-112409334-B Heterocyclic derivatives useful as SHP2 inhibitors 北京加科思新药研发有限公司 2022-12-02 CN disclosed
US-10988466-B2 Heterocyclic derivatives useful as SHP2 inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2021-04-27 US disclosed
US-10988466-B2 Heterocyclic derivatives useful as SHP2 inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2021-04-27 US disclosed
CN-112409334-A Novel heterocyclic derivatives useful as SHP2 inhibitors 北京加科思新药研发有限公司 2021-02-26 CN disclosed
CN-112174935-A Novel heterocyclic derivatives useful as SHP2 inhibitors 北京加科思新药研发有限公司 2021-01-05 CN disclosed
US-20200392128-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2020-12-17 US disclosed
US-20200392128-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2020-12-17 US disclosed
EP-3601239-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS Jacobio Pharmaceuticals Co., Ltd. (CN) 2020-02-05 EP disclosed
WO-2018172984-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2018-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223285-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS PTPN5, PTPN1, PTPRJ LMNA 4869/4885HPGD 2424/4885MAOB 3802/4885
US-10988466-B2 Heterocyclic derivatives useful as SHP2 inhibitors PTPRJ, PTPN5, PTPN1 LMNA 4840/4885HPGD 2504/4885MAOB 3849/4885
US-20200392128-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS PTPN5, PTPN1, PTPRJ LMNA 4869/4885HPGD 2424/4885MAOB 3802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.